JP2015521598A5 - - Google Patents

Download PDF

Info

Publication number
JP2015521598A5
JP2015521598A5 JP2015517321A JP2015517321A JP2015521598A5 JP 2015521598 A5 JP2015521598 A5 JP 2015521598A5 JP 2015517321 A JP2015517321 A JP 2015517321A JP 2015517321 A JP2015517321 A JP 2015517321A JP 2015521598 A5 JP2015521598 A5 JP 2015521598A5
Authority
JP
Japan
Prior art keywords
compound
compound according
pharmaceutically acceptable
acceptable salt
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015517321A
Other languages
English (en)
Japanese (ja)
Other versions
JP6234450B2 (ja
JP2015521598A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/044882 external-priority patent/WO2013188254A1/en
Publication of JP2015521598A publication Critical patent/JP2015521598A/ja
Publication of JP2015521598A5 publication Critical patent/JP2015521598A5/ja
Application granted granted Critical
Publication of JP6234450B2 publication Critical patent/JP6234450B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015517321A 2012-06-11 2013-06-10 5−[5−フェニル−4−(ピリジン−2−イルメチルアミノ)キナゾリン−2−イル]ピリジン−3−スルホンアミドのホスホロアミド酸プロドラッグ Expired - Fee Related JP6234450B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261657913P 2012-06-11 2012-06-11
US61/657,913 2012-06-11
PCT/US2013/044882 WO2013188254A1 (en) 2012-06-11 2013-06-10 Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide

Publications (3)

Publication Number Publication Date
JP2015521598A JP2015521598A (ja) 2015-07-30
JP2015521598A5 true JP2015521598A5 (enExample) 2016-06-30
JP6234450B2 JP6234450B2 (ja) 2017-11-22

Family

ID=48670111

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015517321A Expired - Fee Related JP6234450B2 (ja) 2012-06-11 2013-06-10 5−[5−フェニル−4−(ピリジン−2−イルメチルアミノ)キナゾリン−2−イル]ピリジン−3−スルホンアミドのホスホロアミド酸プロドラッグ

Country Status (34)

Country Link
US (1) US9238666B2 (enExample)
EP (1) EP2858987B1 (enExample)
JP (1) JP6234450B2 (enExample)
KR (1) KR102092984B1 (enExample)
CN (1) CN104350048B (enExample)
AR (1) AR091402A1 (enExample)
AU (1) AU2013274619B2 (enExample)
BR (1) BR112014030629B1 (enExample)
CA (1) CA2876359C (enExample)
CL (1) CL2014003361A1 (enExample)
CO (1) CO7160032A2 (enExample)
CY (1) CY1120432T1 (enExample)
DK (1) DK2858987T3 (enExample)
EA (1) EA024692B1 (enExample)
ES (1) ES2675314T3 (enExample)
HR (1) HRP20180815T8 (enExample)
HU (1) HUE039210T2 (enExample)
IL (1) IL236074A (enExample)
LT (1) LT2858987T (enExample)
MX (1) MX356699B (enExample)
MY (1) MY169219A (enExample)
NZ (1) NZ703632A (enExample)
PE (1) PE20150228A1 (enExample)
PH (1) PH12014502747B1 (enExample)
PL (1) PL2858987T3 (enExample)
PT (1) PT2858987T (enExample)
RS (1) RS57376B1 (enExample)
SG (1) SG11201408076WA (enExample)
SI (1) SI2858987T1 (enExample)
SM (1) SMT201800369T1 (enExample)
TN (1) TN2014000499A1 (enExample)
TW (1) TWI571470B (enExample)
WO (1) WO2013188254A1 (enExample)
ZA (1) ZA201500161B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9050345B2 (en) * 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
US9403834B2 (en) * 2013-03-11 2016-08-02 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
CN105008366B (zh) * 2013-03-11 2017-11-14 百时美施贵宝公司 作为钾离子通道抑制剂的吡咯并哒嗪类化合物
KR20180084049A (ko) * 2015-11-19 2018-07-24 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. 제약 화합물의 아민 전구약물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
GB9514380D0 (en) * 1995-07-13 1995-09-13 Knoll Ag Therapeutic agents
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
ID26984A (id) 1998-07-06 2001-02-22 Bristol Myers Squibb Co Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
ES2215474B1 (es) 2002-12-24 2005-12-16 J. URIACH & CIA S.A. Nuevos derivados de fosforamida.
AR049847A1 (es) 2004-07-29 2006-09-06 Merck & Co Inc Inhibidores de los canales de potasio
EP1838690A2 (en) * 2004-12-21 2007-10-03 Devgen N.V. Compounds with kv4 ion channel activity
EP2473487B1 (en) 2009-09-03 2016-10-26 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
AU2010289321A1 (en) 2009-09-04 2012-04-05 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
NZ604423A (en) * 2010-06-24 2015-01-30 Alkermes Pharma Ireland Ltd Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
US9050345B2 (en) * 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
JP2016516691A (ja) * 2013-03-11 2016-06-09 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company カリウムイオンチャネル阻害剤としてのイソキノリン
US9242966B2 (en) * 2013-03-11 2016-01-26 Bristol-Myers Squibb Company Phthalazines as potassium ion channel inhibitors

Similar Documents

Publication Publication Date Title
JP2013032389A5 (enExample)
JP2016515561A5 (enExample)
JP2014500861A5 (enExample)
JP2015078230A5 (enExample)
JP2013518107A5 (enExample)
JP2010077141A5 (enExample)
JP2012144574A5 (enExample)
WO2017123884A8 (en) Heterocyclic compounds as rsv inhibitors
JP2017518302A5 (enExample)
JP2011518833A5 (enExample)
JP2013509429A5 (enExample)
JP2017537066A5 (enExample)
JP2016530259A5 (enExample)
JP2013525444A5 (enExample)
EP4643945A3 (en) Neuroactive steroids and methods of use thereof
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
JP2015509075A5 (enExample)
JP2014507477A5 (enExample)
JP2014097964A5 (enExample)
JP2015512432A5 (enExample)
JP2016510326A5 (enExample)
JP2015516419A5 (enExample)
JP2016532632A5 (enExample)
JP2013513607A5 (enExample)
JP2016515550A5 (enExample)